David E. I. Pyott - 07 Jun 2023 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Reporting relationship: Director
Issuer ticker: PLRX
Reported as of: 07 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jun 2023, 17:24:38 UTC
Prior SEC filing: 24 May 2023
Next SEC filing: 20 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Mike Ouimette, attorney-in-fact

Key filing fact

David E. I. Pyott filed Form 4 for PLIANT THERAPEUTICS, INC. (PLRX) on 08 Jun 2023.

Key facts

This page summarizes David E. I. Pyott's Form 4 filing for PLIANT THERAPEUTICS, INC. (PLRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jun 2023, 17:24.

Change

Previous filing in this sequence was filed on 24 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PLRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +14,000
Change %
Price: $0.000000
Shares after: 14,000
Date: 07 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,000
Exercise price: $23.09
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 7th, 2023 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 7th, 2023 grant date, or (ii) the 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.